| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/13543784.2015.963195 |
| P698 | PubMed publication ID | 25227476 |
| P50 | author | Tanya Simuni | Q67213333 |
| P2093 | author name string | Anna R Carta | |
| P2860 | cites work | Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology | Q22241657 |
| Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 | ||
| PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease | Q24294809 | ||
| PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease | Q24597726 | ||
| Parkinson's disease, insulin resistance and novel agents of neuroprotection | Q26853311 | ||
| Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis | Q27002540 | ||
| Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression | Q28211928 | ||
| Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat | Q28271669 | ||
| Peroxisome proliferator-activated receptors: nuclear control of metabolism | Q28374684 | ||
| Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons | Q28573124 | ||
| PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes | Q29547229 | ||
| Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance | Q29614354 | ||
| Epidemiology of Parkinson's disease | Q29614901 | ||
| Stages in the development of Parkinson's disease-related pathology | Q29615834 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Exenatide and the treatment of patients with Parkinson's disease | Q30540208 | ||
| Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies | Q34324440 | ||
| Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease | Q34358956 | ||
| Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline | Q34528059 | ||
| Levodopa and the progression of Parkinson's disease | Q34553278 | ||
| Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). | Q34587610 | ||
| A double-blind, delayed-start trial of rasagiline in Parkinson's disease | Q34612128 | ||
| Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates | Q34626758 | ||
| Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. | Q34628009 | ||
| Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 | ||
| Diabetes and risk of Parkinson's disease | Q34718429 | ||
| Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial | Q34985342 | ||
| PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation | Q35053566 | ||
| The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys | Q35196195 | ||
| Pioglitazone and bladder cancer: a population-based study of Taiwanese. | Q35688201 | ||
| Neurodegenerative disorders associated with diabetes mellitus | Q35791191 | ||
| The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study | Q36001145 | ||
| Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study | Q36013549 | ||
| Effects of PPARgamma and combined agonists on the urinary tract of rats and other species | Q36210174 | ||
| Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis | Q36247512 | ||
| Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study | Q36486802 | ||
| Pioglitazone and bladder cancer: a propensity score matched cohort study | Q36562522 | ||
| Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease | Q36656691 | ||
| Sleep and non-motor symptoms in Parkinson's disease | Q36725295 | ||
| PPARs and molecular mechanisms of transrepression | Q36791361 | ||
| Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders | Q36931609 | ||
| Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists | Q36992256 | ||
| The pathogenesis of cell death in Parkinson's disease--2007. | Q37050626 | ||
| Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis | Q37106685 | ||
| Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights | Q37115436 | ||
| PPAR: a therapeutic target in Parkinson's disease. | Q37126858 | ||
| Regulation of Glial Cell Functions by PPAR-gamma Natural and Synthetic Agonists. | Q37157531 | ||
| Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR- γ Agonist against MPTP. | Q37256315 | ||
| Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts | Q37955871 | ||
| Association between pioglitazone and urothelial bladder cancer | Q38012891 | ||
| Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies | Q38061184 | ||
| Pioglitazone and cancer: angel or demon? | Q38070732 | ||
| Shared dysregulated pathways lead to Parkinson's disease and diabetes | Q38078667 | ||
| Obstacles to the development of a neuroprotective therapy for Parkinson's disease | Q38079790 | ||
| PPAR-γ: therapeutic prospects in Parkinson's disease | Q38087378 | ||
| Does Parkinson's disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments? | Q38140969 | ||
| Autonomic dysfunction in Parkinson disease. | Q38149577 | ||
| Molecular Effects of L-dopa Therapy in Parkinson's Disease | Q38346832 | ||
| Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells | Q38735354 | ||
| A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease | Q40254829 | ||
| Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats | Q41294400 | ||
| Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. | Q42454049 | ||
| Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions | Q42455114 | ||
| Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease | Q42650570 | ||
| Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients: effect of pioglitazone | Q43205357 | ||
| Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. | Q43254579 | ||
| Methyl group-donating vitamins elevate 3-O-methyldopa in patients with Parkinson disease | Q43872430 | ||
| A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease | Q44011628 | ||
| Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. | Q44086465 | ||
| Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study | Q44499883 | ||
| A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease | Q44851007 | ||
| PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease | Q46107948 | ||
| Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease | Q46264998 | ||
| Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist | Q46375530 | ||
| A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease | Q46947253 | ||
| Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis | Q47613876 | ||
| Parkinson disease: the controversy of levodopa toxicity in Parkinson disease | Q48749538 | ||
| The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease | Q48932292 | ||
| Clinical features of Parkinson disease when onset of diabetes came first: A case-control study. | Q50948858 | ||
| Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model. | Q52299253 | ||
| Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients. | Q52880488 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 219-227 | |
| P577 | publication date | 2014-09-17 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease | |
| P478 | volume | 24 |
| Q36759960 | A Feed-Forward Circuit of Endogenous PGC-1α and Estrogen Related Receptor α Regulates the Neuronal Electron Transport Chain |
| Q49433973 | Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor |
| Q52640400 | Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson's disease. |
| Q38725286 | Current Challenges Towards the Development of a Blood Test for Parkinson's Disease |
| Q92209538 | Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's Disease |
| Q33734563 | Dissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology |
| Q53649555 | Glitazones inhibit human monoamine oxidase but their anti-inflammatory actions are not mediated by VAP-1/semicarbazide-sensitive amine oxidase inhibition. |
| Q38815779 | Microglial phenotypes in Parkinson's disease and animal models of the disease |
| Q30357397 | Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. |
| Q58714026 | Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets |
| Q30250347 | The current role of thiazolidinediones in diabetes management |
| Q41683709 | The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain |
Search more.